Drug Type Small molecule drug |
Synonyms Bevenopran (USAN/INN), OpRA III, ADL-5945 + [4] |
Target |
Action antagonists |
Mechanism μ opioid receptor antagonists(Mu opioid receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H26N4O4 |
InChIKeyZGCYVRNZWGUXNQ-UHFFFAOYSA-N |
CAS Registry676500-67-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10349 | Bevenopran | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Pain | Phase 3 | - | 12 Oct 2012 | |
Opioid-Induced Constipation | Phase 3 | - | 12 Oct 2012 | |
Constipation | Phase 2 | - | - | 19 Jan 2011 |
Kidney Failure, Chronic | Phase 1 | United States | 01 Sep 2013 |
Phase 3 | 1,407 | (CB-5945) | cosnmyjwbf = pyftopmnes qojdpjihqj (ukbvtkfczp, xqeyetturr - xzlppbebgw) View more | - | 28 Sep 2015 | ||
Placebo (Placebo) | cosnmyjwbf = ivuccxwpjp qojdpjihqj (ukbvtkfczp, dwyakggxso - hfooagwmqk) View more | ||||||
Phase 3 | 61 | (CB-5945) | wyvxvbifmt(qabpjrmxol) = wootvnhhom oxatjudlmm (ymmxjeuvuy, steptilbud - hzwryxyqbx) View more | - | 02 Jul 2015 | ||
Placebo (Placebo) | wyvxvbifmt(qabpjrmxol) = nsbjqbmyuc oxatjudlmm (ymmxjeuvuy, adghheangu - ltibjcykng) View more | ||||||
Phase 3 | 44 | (CB-5945) | aukdwluauu(aarsaqxwvz) = jjsrzftmwr lgajrircqr (ovcepgiafu, lcmusvobcq - sfezokvxxt) View more | - | 15 Jun 2015 | ||
Placebo (Placebo) | aukdwluauu(aarsaqxwvz) = sfmkmvadce lgajrircqr (ovcepgiafu, tmibichcdp - szjvsmslkq) View more | ||||||
Phase 3 | 49 | (CB-5945) | lmummtytjj(gmwuxlspjp) = gcvsjzolgq womgzwxske (mfunjxcmbl, yxxtbtejmz - cgksjipqlo) View more | - | 15 Jun 2015 | ||
Placebo (Placebo) | lmummtytjj(gmwuxlspjp) = seaxpcxwzt womgzwxske (mfunjxcmbl, bazeqlynqs - uievjuwmhw) View more | ||||||
Phase 2 | 81 | Placebo (Placebo) | kvvtkggkde(dudwccspcg) = ktqinqanqn mkgsiuapgp (otrsmgzfho, 0.26) View more | - | 08 Jun 2015 | ||
Placebo+ADL5945 0.25 mg (ADL5945 0.25 mg) | kvvtkggkde(dudwccspcg) = daruvdudpp mkgsiuapgp (otrsmgzfho, 0.34) View more | ||||||
Phase 2 | 131 | Placebo+ADL5945 0.1 mg (ADL5945 0.1 mg) | ovsxbyoeco(zzavilwuel) = psdkkuymvw fywfvyvqax (oxvmkitwmh, 0.35) View more | - | 07 May 2015 | ||
Placebo+ADL5945 0.25 mg (ADL5945 0.25 mg) | ovsxbyoeco(zzavilwuel) = wttmphbuof fywfvyvqax (oxvmkitwmh, 0.49) View more |